论文信息 - A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT). - 字舞流文

A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

M. Buyse | Tae Won Kim | J. Sakamoto | H. Matsumoto | Keun-Wook Lee | K. Muro | S. Morita | L. Shen | R. Xu | T. Satoh | H. Nozawa | H. Uetake | S. Iwasa | T. Nishina | B. Ryoo | Y. Park | Sae-Won Han | K. Yamazaki | Y. Deng